{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:33:21Z","timestamp":1787726001241,"version":"build-2784847793"},"reference-count":31,"publisher":"American Medical Association (AMA)","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"\n Importance<\/jats:title>\n Individuals who experience opioid overdoses are at high risk of death, and data are limited about the comparative effectiveness of medications for this high-risk population.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To compare the effectiveness of methadone and buprenorphine-naloxone in individuals with a past-year history of opioid overdose.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This retrospective cohort study with target trial emulation included individuals who started methadone or buprenorphine-naloxone treatment between January 1, 2017, and December 31, 2023, in Ontario, Canada. Participants had a past-year emergency department visit for an opioid overdose and no use of either medication for 7 days. Individuals starting each medication were matched on a 1:1 basis using propensity scores, sex, and index date. Data were analyzed from November 2024 to June 2026.<\/jats:p>\n <\/jats:sec>\n \n Main outcomes and measures<\/jats:title>\n The primary outcome was death from any cause within 1 year, analyzed using an initiator approach with Cox proportional hazards regression. The secondary outcomes were opioid overdose and treatment discontinuation. Per-protocol analyses evaluating outcomes before medication discontinuation were also conducted.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n A total of 5882 individuals were included in the matched cohort (mean [SD] age, 35.8 [10.8] years; 1888 female [32.1%]). In the methadone-initiating group, 165 individuals (5.6%) died within 1 year, compared with 210 (7.1%) in the buprenorphine-naloxone\u2013initiating group (HR, 0.78; 95% CI, 0.63-0.95;\n P<\/jats:italic>\n \u2009=\u2009.01), with an E-value of 1.9. Median time to treatment discontinuation was 25 days (IQR, 7-131 days) in the methadone group compared with 16 days (IQR, 5-69 days) in the buprenorphine-naloxone group (HR, 0.78; 95% CI, 0.74-0.82;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001). There was no significant difference in the time to first opioid overdose (HR, 1.07; 95% CI, 0.97-1.18;\n P<\/jats:italic>\n \u2009=\u2009.17). In the per-protocol analyses, there was no significant difference in the hazard of death among individuals starting methadone and buprenorphine-naloxone (HR, 0.84; 95% CI, 0.48-1.47;\n P<\/jats:italic>\n \u2009=\u2009.55) and an increased hazard of opioid overdose among individuals starting methadone (HR, 1.52; 95% CI, 1.19-1.93;\n P<\/jats:italic>\n \u2009&amp;lt;\u2009.001).\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this matched cohort of individuals with a past-year opioid overdose, starting methadone was associated with a reduced risk of death during the subsequent year compared with starting buprenorphine-naloxone. Treatment durations were short, particularly among individuals starting buprenorphine-naloxone, and there was no significant difference in mortality during receipt of opioid agonist treatment. These findings may be explained by unmeasured confounding, and epidemiologic studies in other jurisdictions are needed to confirm these findings.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2026.29313","type":"journal-article","created":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:00:27Z","timestamp":1787670027000},"page":"e2629313","source":"Crossref","is-referenced-by-count":1,"title":["Methadone vs Buprenorphine-Naloxone in Opioid Overdose Survivors"],"prefix":"10.1001","volume":"9","author":[{"given":"Robert A.","family":"Kleinman","sequence":"first","affiliation":[{"name":"Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Larney","sequence":"additional","affiliation":[{"name":"Burnet Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naheemot Olaoluwa","family":"Sule","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clement","family":"Ma","sequence":"additional","affiliation":[{"name":"Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Division of Biostatistics, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya S.","family":"Hauck","sequence":"additional","affiliation":[{"name":"Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Kurdyak","sequence":"additional","affiliation":[{"name":"Campbell Family Mental Health Research Institute, Centre for Addiction and Mental Health, Toronto, Ontario, Canada"},{"name":"Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada"},{"name":"ICES, Toronto, Ontario, Canada"},{"name":"Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2026,8,25]]},"reference":[{"issue":"21","key":"zoi260798r1","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1001\/jama.2026.6469","article-title":"One-year mortality among opioid overdose survivors.","volume":"335","author":"Kleinman","year":"2026","journal-title":"JAMA"},{"issue":"38","key":"zoi260798r4","doi-asserted-by":"publisher","first-page":"E1280","DOI":"10.1503\/cmaj.241173","article-title":"Management of opioid use disorder: 2024 update to the national clinical practice guideline.","volume":"196","author":"Yakovenko","year":"2024","journal-title":"CMAJ"},{"issue":"9","key":"zoi260798r5","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1001\/jamapsychiatry.2021.0976","article-title":"Association of opioid agonist treatment with all-cause mortality and specific causes of death among people with opioid dependence: a systematic review and meta-analysis.","volume":"78","author":"Santo","year":"2021","journal-title":"JAMA Psychiatry"},{"issue":"3","key":"zoi260798r6","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/M17-3107","article-title":"Medication for opioid use disorder after nonfatal opioid overdose and association with mortality: a cohort study.","volume":"169","author":"Larochelle","year":"2018","journal-title":"Ann Intern Med"},{"key":"zoi260798r7","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209218","article-title":"Association of medications for opioid use disorder with reduced risk of repeat opioid overdose in Medicaid: a cohort study.","volume":"157","author":"Tipping","year":"2024","journal-title":"J Subst Use Addict Treat"},{"issue":"10","key":"zoi260798r8","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1176\/appi.ajp.21090964","article-title":"Flexible buprenorphine\/naloxone model of care for reducing opioid use in individuals with prescription-type opioid use disorder: an open-label, pragmatic, noninferiority randomized controlled trial.","volume":"179","author":"Jutras-Aswad","year":"2022","journal-title":"Am J Psychiatry"},{"issue":"18","key":"zoi260798r9","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1056\/NEJM200011023431802","article-title":"A comparison of levomethadyl acetate, buprenorphine, and methadone for opioid dependence.","volume":"343","author":"Johnson","year":"2000","journal-title":"N Engl J Med"},{"issue":"8","key":"zoi260798r10","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"issue":"16","key":"zoi260798r11","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1001\/jama.2023.4221","article-title":"Emulation of randomized clinical trials with nonrandomized database analyses: results of 32 clinical trials.","volume":"329","author":"Wang","year":"2023","journal-title":"JAMA"},{"issue":"5","key":"zoi260798r12","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1001\/jamapediatrics.2026.0041","article-title":"Comparative effectiveness of buprenorphine-naloxone and methadone for opioid overdose among youths.","volume":"180","author":"Kleinman","year":"2026","journal-title":"JAMA Pediatr"},{"key":"zoi260798r13","doi-asserted-by":"publisher","DOI":"10.1016\/j.dadr.2024.100240","article-title":"Fentanyl, carfentanil and other fentanyl analogues in Canada\u2019s illicit opioid supply: A cross-sectional study.","volume":"12","author":"Kleinman","year":"2024","journal-title":"Drug Alcohol Depend Rep"},{"issue":"7","key":"zoi260798r14","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2025.18389","article-title":"Duration of methadone and buprenorphine-naloxone treatment.","volume":"8","author":"Kleinman","year":"2025","journal-title":"JAMA Netw Open"},{"issue":"9","key":"zoi260798r15","doi-asserted-by":"publisher","first-page":"E247","DOI":"10.1503\/cmaj.170958","article-title":"Management of opioid use disorders: a national clinical practice guideline.","volume":"190","author":"Bruneau","year":"2018","journal-title":"CMAJ"},{"issue":"7","key":"zoi260798r16","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1111\/add.15862","article-title":"Duration of use and outcomes among people with opioid use disorder initiating methadone and buprenorphine in Ontario: a population-based propensity-score matched cohort study.","volume":"117","author":"Gomes","year":"2022","journal-title":"Addiction"},{"key":"zoi260798r17","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109464","article-title":"The impact of opioid agonist treatment on fatal and non-fatal drug overdose among people with a history of opioid dependence in NSW, Australia, 2001-2018: findings from the OATS retrospective linkage study.","volume":"236","author":"Jones","year":"2022","journal-title":"Drug Alcohol Depend"},{"key":"zoi260798r18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108647","article-title":"Assessing the determinants of completing OAT induction and long-term retention: a population-based study in British Columbia, Canada.","volume":"133","author":"Kurz","year":"2022","journal-title":"J Subst Abuse Treat"},{"issue":"12","key":"zoi260798r19","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1001\/jamapsychiatry.2023.3145","article-title":"Gabapentin use among individuals initiating buprenorphine treatment for opioid use disorder.","volume":"80","author":"Ellis","year":"2023","journal-title":"JAMA Psychiatry"},{"issue":"7","key":"zoi260798r21","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1089\/cap.2019.0013","article-title":"Risk factors for drug overdose in young people: a systematic review of the literature.","volume":"29","author":"Lyons","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"issue":"3","key":"zoi260798r22","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1111\/add.15168","article-title":"Incidence and factors associated with discontinuation of opioid agonist therapy among people who inject drugs in Australia.","volume":"116","author":"Geddes","year":"2021","journal-title":"Addiction"},{"issue":"3","key":"zoi260798r23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies.","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"zoi260798r24","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.csda.2013.12.006","article-title":"Sample size determination for paired right-censored data based on the difference of Kaplan-Meier estimates.","volume":"74","author":"Su","year":"2014","journal-title":"Comput Stat Data Anal"},{"issue":"16","key":"zoi260798r25","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.1002\/sim.5705","article-title":"The performance of different propensity score methods for estimating marginal hazard ratios.","volume":"32","author":"Austin","year":"2013","journal-title":"Stat Med"},{"issue":"21","key":"zoi260798r26","doi-asserted-by":"publisher","first-page":"1822","DOI":"10.1001\/jama.2024.16954","article-title":"Buprenorphine\/naloxone vs methadone for the treatment of opioid use disorder.","volume":"332","author":"Nosyk","year":"2024","journal-title":"JAMA"},{"issue":"6","key":"zoi260798r27","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S2215-0366(23)00095-0","article-title":"Buprenorphine versus methadone for the treatment of opioid dependence: a systematic review and meta-analysis of randomised and observational studies.","volume":"10","author":"Degenhardt","year":"2023","journal-title":"Lancet Psychiatry"},{"issue":"5","key":"zoi260798r28","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1097\/ADM.0000000000000950","article-title":"Office-based methadone prescribing for opioid use disorder: the Canadian model.","volume":"16","author":"Kleinman","year":"2022","journal-title":"J Addict Med"},{"key":"zoi260798r29","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2022-071467","article-title":"Is daily supervised buprenorphine-naloxone dosing necessary?","volume":"378","author":"Kleinman","year":"2022","journal-title":"BMJ"},{"issue":"5","key":"zoi260798r30","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1001\/jamapsychiatry.2019.4170","article-title":"All-cause and cause-specific mortality among people using extramedical opioids: a systematic review and meta-analysis.","volume":"77","author":"Larney","year":"2020","journal-title":"JAMA Psychiatry"},{"key":"zoi260798r31","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111087","article-title":"Mortality risk and causes of death among people who use opioids in a take-home naloxone cohort.","volume":"255","author":"Ericson","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"zoi260798r2","first-page":"1","article-title":"The ASAM National Practice Guideline for the Treatment of Opioid Use Disorder: 2020 Focused Update.","volume-title":"J Addict Med","author":"American Society of Addiction Medicine (ASAM)","year":"2020"},{"key":"zoi260798r20","author":"College of Physicians and Surgeons of Ontario","year":"2011"},{"key":"zoi260798r3","unstructured":"Department of Health and Social Care. Oral methadone and buprenorphine: recommendations. Accessed July 25, 2025. https:\/\/www.gov.uk\/government\/publications\/medicine-choices-in-opioid-substitution-treatment\/oral-methadone-and-buprenorphine-recommendations"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2853267\/kleinman_2026_oi_260798_1787073370.85982.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:00:28Z","timestamp":1787670028000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2853267"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,25]]},"references-count":31,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2026.29313","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,25]]}}}